-- Allegion Public (ALLE) has an average rating of overweight and mean price target of $167.36, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $139.24, Change: $+1.38, Percent Change: +1.00%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target by $4 to $78, based on a 14x EV/EBITDA multiple applied to our 2026 EBITDA estimate of $814M (raised from $770M; +11% Y/Y growth). We lift our 2026 EPS to $5.32 from $4.62 and 2027's to $5.72 from $4.91. ETSY delivered a strong Q1 beat, with GMS rising 5.5% Y/Y and active buyers returning to modest Q/Q growth. That said, results benefited from several one-time tailwinds, including FX (a 190 bps lift to GMS) and higher average order values due to tariffs and the removal of de minimis. The company's Q2 outlook, calling for GMS growth of 3%-5% Y/Y, suggests near-term momentum is intact. The key debate shifts to the back half of the year, when comps become more challenging. We remain constructive, supported by improving customer metrics, including stabilizing repeat and habitual buyer trends, which we attribute to recent app enhancements (e.g., personalization, discovery). We also expect a sizable share repurchase following the $1.2B Depop sale, which is anticipated to close by Q3.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our price target by CAD36 to CAD102, 11.5x our FY 26 (Sep.) EPS view, below CGI's three-year average (~18x) on macro uncertainty and U.S. Federal risks. We lower our FY 26 EPS view by CAD0.02 to CAD8.88 and lower FY 27's by CAD0.12 to CAD9.40. We are concerned that Q2's continued sales deceleration (+1.6% ex-FX, -180 bps Q/Q, -170 bps Y/Y) reflects structural pressure rather than just temporary issues. Q2's bookings decline (-4% Y/Y) and lower TTM book-to-bill of 108.4% (-220-bps Y/Y) also signal risk as clients keep delaying spending decisions, and we note the decline came despite strong bookings performance in U.S. Federal (TTM book-to-bill of 110.9%), where CGI's expectation of an organic sales growth resumption in Q3 carries uncertainty and may be overshadowed by European weakness, in our view. The company's lack of formal guidance increases our uncertainty. Nonetheless, a below-historical valuation and targeted Q3 organic sales pickup in U.S. Federal offer near-term upside if CGI can execute.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $398, 17.1x our new 2027 EPS estimate, above AMGN's 10-year historical forward average of 14.1x, justified by its strengthening outlook. We raise our 2026 EPS view to $22.56 from $22.15 and our 2027 EPS to $23.23 from $22.83. AMGN delivered a strong Q1, showcasing significant positive momentum across its business. The company's six core growth drivers generated $5.6 billion in the quarter, growing 24% Y/Y. Standout performers included Repatha, with 34% Y/Y sales growth and the rare disease drug Uplinza, which saw sales surge 188% Y/Y. In terms of pipeline advancement, we continue to view the developments on Amgen's obesity treatment candidate, MariTide, as encouraging. AMGN announced new Phase III trials to explore less frequent dosing schedules (every eight or 12 weeks), a key potential differentiator, in our view. MariTide's potential for monthly or even less frequent (quarterly) dosing could be an important differentiator that would improve patient convenience and long-term adherence.